AZN.UK

11,354

+1.01%↑

GSK

1,473

+0.72%↑

HLN.UK

391.5

-0.05%↓

AZN.UK

11,354

+1.01%↑

GSK

1,473

+0.72%↑

HLN.UK

391.5

-0.05%↓

AZN.UK

11,354

+1.01%↑

GSK

1,473

+0.72%↑

HLN.UK

391.5

-0.05%↓

AZN.UK

11,354

+1.01%↑

GSK

1,473

+0.72%↑

HLN.UK

391.5

-0.05%↓

AZN.UK

11,354

+1.01%↑

GSK

1,473

+0.72%↑

HLN.UK

391.5

-0.05%↓

Search

Indivior PLC

Closed

740.5 1.79

Overview

Share price change

24h

Current

Min

714

Max

747.5

Key metrics

By Trading Economics

Income

63M

66M

Sales

-8M

299M

P/E

Sector Avg

386.5

73.239

EPS

0.319

Profit margin

22.074

Employees

1,030

EBITDA

97M

106M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+53.21% upside

Dividends

By Dow Jones

Next Earnings

24 Apr 2025

Market Stats

By TradingEconomics

Market Cap

38M

974M

Previous open

738.71

Previous close

740.5

Indivior PLC Chart

Past performance is not a reliable indicator of future results.

Related News

1 Apr 2025, 23:15 UTC

Major Market Movers

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

1 Apr 2025, 23:46 UTC

Market Talk

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

1 Apr 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 Apr 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

1 Apr 2025, 23:44 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

1 Apr 2025, 23:43 UTC

Market Talk

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

1 Apr 2025, 23:02 UTC

Market Talk

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

1 Apr 2025, 22:26 UTC

Market Talk

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

1 Apr 2025, 21:06 UTC

Market Talk

Mexican Remittances See Slow Start to the Year -- Market Talk

1 Apr 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

1 Apr 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

1 Apr 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 Apr 2025, 20:20 UTC

Top News

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

1 Apr 2025, 20:15 UTC

Acquisitions, Mergers, Takeovers

Eaton Completes Acquisition Of Fibrebond >ETN

1 Apr 2025, 20:11 UTC

Market Talk

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

1 Apr 2025, 20:07 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1 Apr 2025, 19:46 UTC

Top News

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

1 Apr 2025, 19:43 UTC

Market Talk

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

1 Apr 2025, 19:17 UTC

Top News

Meta's Head of AI Research to Resign Amid Computing Push -- Update

1 Apr 2025, 19:13 UTC

Market Talk

U.S. Natural Gas Futures Give Back Gains -- Market Talk

1 Apr 2025, 19:03 UTC

Market Talk

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

1 Apr 2025, 19:00 UTC

Market Talk

Gold Slips Ahead of Tariff Day -- Market Talk

1 Apr 2025, 18:54 UTC

Market Talk

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

1 Apr 2025, 18:51 UTC

Market Talk

Weaker Dollar Could Add Headwinds for Airlines -- Market Talk

1 Apr 2025, 18:47 UTC

Acquisitions, Mergers, Takeovers

CoreWeave Stock Rebounds From Selloff. Count On More Volatility. -- Barrons.com

1 Apr 2025, 18:07 UTC

Top News

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

1 Apr 2025, 17:16 UTC

Market Talk

Oil Futures Slip From Five-Week Highs -- Market Talk

1 Apr 2025, 16:25 UTC

Market Talk

Trump Tariff Plans Look Counterproductive for Industry -- Market Talk

1 Apr 2025, 16:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 Apr 2025, 16:25 UTC

Market Talk

Economists Lower Mexico GDP Growth Estimates -- Market Talk

Peer Comparison

Price change

Indivior PLC Forecast

Price Target

By TipRanks

53.21% upside

12 Months Forecast

Average 1,111.52 GBX  53.21%

High 1,238.264 GBX

Low 975 GBX

Based on 6 Wall Street analysts offering 12 month price targets forIndivior PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.